ELIQUIS Reduces Stroke and Systemic Embolism Compared to Warfarin in ARISTOTLE trial

Bristol-Myers Squibb NYSE: BMY) and Pfizer PFE today announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with ELIQUIS® compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. These results of a subanalysis from the ARISTOTLE clinical trial were published today in The Lancet. Stroke and bleeding risk were based on the CHADS2, CHA2DS2VASc, and HAS-BLED scores, which are patient assessment tools used by physicians to help predict the risk of stroke and of bleeding in patients with atrial fibrillation. Physicians can use these risk scores See full press release